Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Josef S. Smolen¹, Stanley Cohen², Paul Emery³, William F C Rigby⁴, Yoshiya Tanaka⁵, Ying Zhang⁶, Alan Friedman⁶, Ahmed A. Othman⁶, Heidi S. Camp⁶ and Aileen L. Pangan⁶, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Metroplex Clinical Research Center, Dallas, TX, ³Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, ⁴Dartmouth College, Hanover, NH, ⁵Univ of Occupational and Environmental Health, Kitakyushu, Japan, ⁶AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…
Abstract Number: 2103 • 2018 ACR/ARHP Annual Meeting
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Nathan Mortimer, Mary Fischer, Ashley Waring and Victoria DeMichel, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: The objective of our research is to understand the genetic architecture and molecular mechanisms that contribute to the development and progression of the autoimmune…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 2105 • 2018 ACR/ARHP Annual Meeting
Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
Pooja KR, Brooklynne Thielen, Xavier Hernandez and Nathan Mortimer, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with various immunological abnormalities and a diverse range of clinical symptoms. In contrast to the…
Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
Abstract Number: 962 • 2018 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, Terence P. Rooney⁴, Christina L. Dickson⁴, Xiao-Yan Yang⁴, Chadi Saifan⁴, Anabela Cardoso⁴, Maher Issa⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved for the treatment of moderately to severely active…
Abstract Number: 2517 • 2018 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis
Peter C. Taylor¹, Bryan Downie², Luting Zhuo², Yevgeniy Gindin², Jacqueline Tarrant³, Jinfeng Liu², René Galien⁴ and Amer M Mirza⁵, ¹University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Bioinformatics, Gilead Sciences Inc., Foster City, CA, ³Gilead Sciences Inc., Foster City, CA, ⁴Galapagos SASU, Romainville, France, ⁵Biomarker Sciences, Gilead Sciences Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral JAK1- selective inhibitor, has shown good safety and efficacy in active rheumatoid arthritis (RA) patients with inadequate response to MTX…
Abstract Number: 997 • 2018 ACR/ARHP Annual Meeting
The Effects of the Jak-Stat Signal Pathway Inhibition on Collagen Biosynthesis in Fibroblast Cell Culture
Mehtap ŞAHİN¹, Hüseyin AYDIN¹, Ahmet ALTUN², Mehmet Emin DERİN³ and Ali Şahin⁴, ¹Biochemistry, Cumhuriyet University Medical Faculty, sivas, Turkey, ²Pharmacology, Cumhuriyet University Medical Faculty, sivas, Turkey, ³Rheumatology-internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁴Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Background/Purpose: Uncontrolled collagen synthesis and deposition occur in various diseases such as hepatic fibrosis, scleroderma.Tofacitinib is a selective JAK-kinase (1/3)inhibitor.Currently it is used in the…
Abstract Number: 2518 • 2018 ACR/ARHP Annual Meeting
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Alan J. Kivitz¹, Daksha P Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie Di Paolo⁴, Neelufar Mozaffarian³, Sean Hsueh³, JiYun Kim⁵, Wendy Jiang³, Lin Liu³, John S. Sundy⁶ and Mark C. Genovese⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Center for Arthritis and Osteoporosis, Elizabethtown, KY, ³Gilead Sciences, Inc., Foster City, CA, ⁴Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA, ⁵Biomarkers, Gilead Sciences, Inc., Foster City, CA, ⁶Clinical Research, Inflammation and Respiratory, Gilead Sciences, Inc., Foster City, CA, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK…
Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Mark C. Genovese¹, Roy Fleischmann², Bernard Combe³, Stephen Hall⁴, Ying Zhang⁵, Yijie Zhou⁵, Mohamed-Eslam F. Mohamed⁶, Sebastian Meerwein⁷ and Aileen L. Pangan⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, ⁵AbbVie Inc., North Chicago, IL, ⁶Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting
An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Eric Gracey^1,2, Melissa Lim², Zoya Qaiyum¹, Yuriy Baglaenko^1,2, Wenyan Miao³, Craig Masse³, William Westlin³ and Robert D Inman^1,4, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Nimbus Therapeutics, Cambridge, MA, ⁴Toronto Western Hospital, University Health Network, toronto, ON, Canada
Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…
Abstract Number: 2866 • 2017 ACR/ARHP Annual Meeting
Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Paul Emery¹, Peter C. Taylor², Michael Weinblatt³, Yoshiya Tanaka⁴, Edward C. Keystone⁵, Ernst R. Dow⁶, Richard Higgs⁶, William L. Macias⁶, Guilherme Rocha⁶, Terence P. Rooney⁶, Douglas E. Schlichting⁶, Steven H. Zuckerman⁶ and Iain B. McInnes⁷, ¹Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ²NDORMS, University of Oxford, Oxford, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵University of Toronto, Toronto, ON, Canada, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In RA-BEAM (NCT01710358), baricitinib (BARI), an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, yielded significant improvements in patients (pts) with…
Abstract Number: 826 • 2017 ACR/ARHP Annual Meeting
TGF-β-Induced Epigenetic Silencing of SOCS3 Facilitates STAT3 Signaling to Promote Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Clara Dees¹, Yun Zhang², Sebastian Poetter¹, Christina Bergmann³, Andreas Ramming⁴, Oliver Distler⁵, Georg Schett⁶ and Jörg Distler⁷, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Tissue fibrosis caused by pathological activation of fibroblasts is a major hallmark of systemic sclerosis (SSc). Although fibroblast activation is initially driven by external…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].